antibody

Interleukin-1 RA (hIL-1RA) Biotin

MBS395589

0.2 mg

315 USD

polyclonal

rabbit

biotin

ELISA, enzyme immunoassay

Antibody

Interleukin-1 RA (hIL-1RA) Biotin

Interleukin-1 RA (hIL-1RA)

IL1RA; Rabbit anti human Interleukin 1 RA; Biotin conjugate

interleukin-1 receptor antagonist protein isoform 3; Interleukin-1 receptor antagonist protein; interleukin-1 receptor antagonist protein; IL1 inhibitor; IL1RN (IL1F3); type II interleukin-1 receptor antagonist; intracellular IL-1 receptor antagonist type II; intracellular interleukin-1 receptor antagonist (icIL-1ra); interleukin 1 receptor antagonist; ICIL-1RA; IL1 inhibitor

IL-1RA

IL1RN; IL1RN; DIRA; IRAP; IL1F3; IL1RA; MVCD4; IL-1RN; IL-1ra; IL-1ra3; ICIL-1RA; IL1F3; IL1RA; IL-1RN; IL-1ra; IRAP

IL1RA_HUMAN

Polyclonal

IgG

Rabbit

Human

159

Protein A/G Chromatography

Provided as solution in phosphate buffered saline with 0.08% sodium azide

1mg/ml

Product should be stored at -20 degree C. Aliquot to avoid freeze/thaw cycles. Stability: Antibodies are stable for one year from purchase if stored frozen.

ELISA (EIA)

ELISA:This antibody has been used as a solution-phase antibody at 2ug/ml in a two-site ELISA with unconjugated IL-1ra antibody. Typically the ELISA has a working range of 27-2000pg/ml and a sensitivity of 85% in the ELISA. Can also be used for immunoprecipitation in solution using a double-antibody method and Western Blot at 10ug/ml.

Immunogen: Human recombinant interleukin 1 receptor antagonist (hIL-1RA). Acession Number: P18510,Human

Positive Control: Specificity: Recognizes human IL-1RA. Does not recognize hIL-1alpha, hIL-1beta or a panel of other human cytokines.

Polyclonal Antibody; Cytokines

Produced by activated macrophages, IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity. IL-1 proteins are involved in the inflammatory response, being identified as endogenous pyrogens, and are reported to stimulate the release of prostaglandin and collagenase from synovial cells. The lack of a specific hydrophobic segment in the precursor sequence suggests that IL-1 is released by damaged cells or is secreted by a mechanism differing from that used for other secretory proteins.

10835147

NP_000568.1

NM_000577.4

P18510

30.748

Cytokine Signaling In Immune System Pathway (366171); IL-1 Signaling Pathway (198908); IL1-mediated Signaling Events Pathway (137944); Immune System Pathway (106386); Interleukin-1 Signaling Pathway (160141); Leptin Signaling Pathway (672456); SIDS Susceptibility Pathways (198901); Signaling By Interleukins Pathway (160140)

The protein encoded by this gene is a member of the interleukin 1 cytokine family. This protein inhibits the activities of interleukin 1, alpha (IL1A) and interleukin 1, beta (IL1B), and modulates a variety of interleukin 1 related immune and inflammatory responses. This gene and five other closely related cytokine genes form a gene cluster spanning approximately 400 kb on chromosome 2. A polymorphism of this gene is reported to be associated with increased risk of osteoporotic fractures and gastric cancer. Four alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]

Function: Inhibits the activity of interleukin-1 by binding to receptor IL1R1 and preventing its association with the coreceptor IL1RAP for signaling. Has no interleukin-1 like activity. Binds functional interleukin-1 receptor IL1R1 with greater affinity than decoy receptor IL1R2; however, the physiological relevance of the latter association is unsure. Ref.17. Subcellular location: Isoform 1: Secreted. Isoform 2: Cytoplasm. Isoform 3: Cytoplasm. Isoform 4: Cytoplasm. Tissue specificity: The intracellular form of IL1RN is predominantly expressed in epithelial cells. Involvement in disease: Microvascular complications of diabetes 4 (MVCD4) [MIM:612628]: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.Note: Disease susceptibility is associated with variations affecting the gene represented in this entry.Interleukin 1 receptor antagonist deficiency (DIRA) [MIM:612852]: A rare autoinflammatory disease of skin and bone resulting in sterile multifocal osteomyelitis, periostitis, and pustulosis from birth. The term autoinflammatory disease describes a group of disorders characterized by attacks of seemingly unprovoked inflammation without significant levels of autoantibodies and autoreactive T-cells.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.21. Pharmaceutical use: Available under the name Kineret (Amgen). Used for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis.

0.2 mg

315 USD